Related Experiment Video
Updated: Jun 28, 2025
In Vitro Selection of Engineered Transcriptional Repressors for Targeted Epigenetic Silencing
Published on: May 5, 2023
Targeting EED as a key PRC2 complex mediator toward novel epigenetic therapeutics
Qichao Bao1, Anil Kumar1, Daqing Wu2
1Chemical Biology Program, Department of Pharmacology and Toxicology, University of Texas Medical Branch, Galveston, TX 77555, USA.
Abstract:
EED within the PRC2 complex is crucial for chromatin regulation particularly in tumor development, making its inhibition a promising epigenetic therapeutic strategy. Significant advancement in PRC2 inhibitor development has been achieved with an approved EZH2 inhibitor in the market and with others in the clinical trials. However, current EZH2 inhibitors are limited to specific blood cancers and encounter therapeutic resistance. EED stabilizes PRC2 complex and enhances its activity through unique allosteric mechanisms, thereby acting as both a scaffold protein and a recognizer of H3K27me3 making it an attractive drug target. This review provides an overview of epigenetic therapeutic strategies targeting EED, including allosteric inhibitors, PPI inhibitors, and PROTACs, together with brief discussions on the relevant challenges, opportunities, and future directions.
Insights
Targeting EED (Embryonic Ectoderm Development) in the PRC2 complex offers a novel epigenetic therapy for cancer. This review explores EED inhibitors, including allosteric and PPI inhibitors, and PROTACs, addressing challenges and future directions.
Area of Science:
- Epigenetics
- Cancer Biology
- Pharmacology
Background:
- The Polycomb Repressive Complex 2 (PRC2) is vital for chromatin regulation and implicated in tumor development.
- While EZH2 inhibitors exist, they face limitations in treating specific blood cancers and drug resistance.
- EED (Embryonic Ectoderm Development) is a key component of PRC2, stabilizing the complex and recognizing H3K27me3, making it an attractive therapeutic target.
Purpose of the Study:
- To provide a comprehensive overview of epigenetic therapeutic strategies targeting EED within the PRC2 complex.
- To discuss the mechanisms and potential of various EED-targeting agents.
- To explore the challenges, opportunities, and future directions in developing EED-based cancer therapies.
Main Methods:
- Literature review of preclinical and clinical studies on EED-targeting epigenetic therapies.
- Analysis of different inhibitor classes, including allosteric inhibitors, protein-protein interaction (PPI) inhibitors, and Proteolysis Targeting Chimeras (PROTACs).
- Discussion of resistance mechanisms and strategies to overcome them.
Main Results:
- Significant advancements have been made in developing PRC2 inhibitors, with approved EZH2 inhibitors and others in clinical trials.
- EED-targeting strategies, including allosteric inhibitors, PPI inhibitors, and PROTACs, show promise for broader applications beyond current EZH2 inhibitor limitations.
- Challenges such as specificity, delivery, and resistance need to be addressed for successful clinical translation.
Conclusions:
- Targeting EED represents a promising epigenetic therapeutic strategy for various cancers, potentially overcoming limitations of current EZH2 inhibitors.
- Further research into novel EED inhibitors and combination therapies is crucial for enhancing efficacy and managing resistance.
- Developing EED-based therapies holds significant potential for future cancer treatment paradigms.
